Peterattiamd

Outlive: The Science and Art of Longevity became a number one New York Times Bestseller and lays out Attia's argument that modern medicine waits too long—focusing on treating disease rather than preventing it decades in advance. The book introduces his Medicine 3.0 framework and covers the interventions he believes matter most for extending both lifespan and healthspan, including exercise, nutrition, sleep, emotional health, and select medications.

Medicine 3.0 is Attia's framework for proactive, personalized healthcare that aims to prevent the chronic diseases of aging—cardiovascular disease, cancer, neurodegeneration, and metabolic dysfunction—long before symptoms appear. He contrasts it with what he calls Medicine 2.0, the current reactive system that waits for a diagnosis before taking serious action. Early Medical, the practice he founded, is built entirely around these principles.

Peter Attia founded Early Medical, a concierge-style practice built around the principles of Medicine 3.0. The practice focuses on helping patients extend both their lifespan and their healthspan through deeply personalized, data-driven interventions rather than waiting for disease to develop.

Yes, Attia has explored research suggesting that fasting before or during chemotherapy may enhance the treatment's effectiveness while reducing toxic side effects on healthy cells. The reasoning is that cancer cells and normal cells respond very differently to a fasted metabolic state, potentially making tumors more vulnerable to chemotherapy drugs. He has discussed this topic in clips from The Drive podcast.

Attia has publicly warned that scammers are producing AI-generated deepfake videos that use his likeness and voice to promote health or financial products he has never endorsed. He urges followers to verify the source of any video before trusting its recommendations, since these fakes can be difficult to identify at a glance.

In his content with renowned lipidologist Tom Dayspring, Attia explains that LDL-C alone is an incomplete picture—factors like LDL particle number, oxidized LDL, systemic inflammation, and the cumulative lifetime exposure to elevated LDL all shape actual cardiovascular risk. This is central to his argument that standard cholesterol panels miss critical information and that cardiovascular risk assessment needs to be far more nuanced.

Attia has been publicly open about his personal use of rapamycin—an immunosuppressant that has shown lifespan-extending effects in animal studies—as part of his own experimental longevity protocol. He is careful to frame it as an off-label decision made with close medical monitoring, and he discusses both the potential benefits and the real unknowns on The Drive podcast and in Outlive.

Peter Attia earned his MD from Stanford University School of Medicine. He subsequently completed a general surgery residency at Johns Hopkins Hospital and worked at the National Cancer Institute, a background that shapes his highly evidence-based and research-driven approach to longevity medicine.

The Drive is Attia's long-form podcast covering longevity, medicine, nutrition, and human performance, featuring in-depth interviews with leading researchers, clinicians, and scientists. It has become one of the most listened-to health and medicine podcasts globally, known for its technical depth and willingness to challenge mainstream medical guidelines. Many episodes are also released as short clips on YouTube and Instagram.

Attia defines lifespan as simply how long you live, while healthspan refers to the quality and functional capacity of those years—how well you move, think, and feel as you age. His central argument in both Outlive and on The Drive is that medicine should optimize both simultaneously, rather than just adding years that may be spent in significant physical or cognitive decline.